VE 202
Alternative Names: JNJ 67670187; VE-202Latest Information Update: 25 Jul 2024
At a glance
- Originator Vedanta Biosciences
- Developer Janssen; Vedanta Biosciences
- Class Anti-inflammatories; Bacteria
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators; Regulatory T-lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Inflammatory bowel diseases; Ulcerative colitis
- No development reported Autoimmune disorders
Most Recent Events
- 08 May 2024 Phase-II clinical trials in Ulcerative colitis (In adults, In the elderly) in United Kingdom, Ukraine, Poland, Czech Republic, Bulgaria, Australia (PO) (NCT05370885)
- 28 Nov 2023 Vedanta Biosciences has patent protection for cover compositions of clostridia bacterial species in European Union
- 04 Oct 2023 VE 202 receives Fast Track designation for Ulcerative colitis [PO,Capsule] (In the elderly, In adults) in USA